CA-MILESTONE-TECH
8.1.2021 01:32:27 CET | Business Wire | Press release
Milestone Technologies, a Silicon Valley based global IT managed services firm, announced today the acquisition of Covestic, LLC. a ServiceNow Elite Partner and IT Managed Services firm, based in Kirkland, WA, USA. The acquisition extends Milestone’s footprint to the US Pacific Northwest and bolsters their IT Managed Services portfolio.
Covestic brings fifteen years of experience in IT Service Management and IT Operations across many industries. The company helps clients drive digital transformation with their wealth of hands-on service management experience, intellectual property and a track record of successful ServiceNow implementations. Their highly skilled consultants collaborate closely with clients to provide the right solutions and approach to ensure streamlined management and delivery of IT services.
“I am thrilled to welcome the Covestic team, their customers, and partners to the Milestone family. We are very excited about the capabilities Covestic adds to the Milestone services portfolio and our teams will collaborate to drive innovation and significant value for clients,” said Sameer Kishore, Milestone’s President and CEO . “Covestic and Milestone share very similar values with a strong focus on employee experience and providing best-in-class services to clients utilizing a high-touch model.”
“We are excited to be joining the Milestone family and I am looking forward to working with our new colleagues to continue to deliver world-class services and solutions to our clients,” said John Schaffer, President and CEO of Covestic . “Given Milestone’s service portfolio and presence in over 36 countries, we now have a broader set of capabilities and an expanded footprint to help our clients in their global digital transformation journeys. This acquisition also provides our employees with greater opportunities for career growth and development.”
About Milestone Technologies
Milestone Technologies is a global managed services provider based in Silicon Valley and has been providing diverse IT Managed Services since 1997, helping hundreds of leading corporations deliver technology around the globe. The company employs 2,600+ industry professionals, serves over 200 clients, and operates in 36 different countries. For more information, please visit www.milestone.tech and follow Milestone Technologies on LinkedIn
About Covestic
Covestic headquartered in Kirkland, WA, has deep expertise in IT Managed Services and ServiceNow as well as the key business processes that ServiceNow enables to include IT Service Management (ITSM), IT Operations Management (ITOM), Customer Service Management (CSM), Security Operations (Security Ops) and Governance Risk and Compliance (GRC). As a partner vested in the ongoing success of their customers, Covestic offers expertise spanning implementation, roadmap planning, platform enablement and managed services for the ServiceNow platform and other IT Managed Services capabilities. For more information, please visit www.covestic.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210107005841/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom